Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy
Autore:
Younossi, ZM; Mullen, KD; Zakko, W; Hodnick, S; Brand, E; Barnes, DS; Carey, WD; McCullough, AC; Easley, K; Boparai, N; Gramlich, T;
Indirizzi:
Cleveland Clin Fdn, Dept Gastroenterol Biostat & Anat Pathol, Cleveland, OH 44195 USA Cleveland Clin Fdn Cleveland OH USA 44195 Pathol, Cleveland, OH 44195 USA Case Western Reserve Univ, Metrohlth Med Ctr, Div Gastroenterol, Cleveland, OH 44106 USA Case Western Reserve Univ Cleveland OH USA 44106 Cleveland, OH 44106 USA Cleveland HCV Consortium, Cleveland, OH USA Cleveland HCV Consortium Cleveland OH USA Consortium, Cleveland, OH USA
Titolo Testata:
JOURNAL OF HEPATOLOGY
fascicolo: 1, volume: 34, anno: 2001,
pagine: 128 - 133
SICI:
0168-8278(200101)34:1<128:ARDCTO>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
VIRUS-INFECTION; THERAPY; COMBINATION; IMPROVEMENT;
Keywords:
hepatitis C; interferon-non-responders; amantadine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Younossi, ZM Inova Fairfax Hosp, Ctr Liver Dis, 3300 Gallows Rd, Falls Church, VA 22042USA Inova Fairfax Hosp 3300 Gallows Rd Falls Church VA USA 22042
Citazione:
Z.M. Younossi et al., "A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy", J HEPATOL, 34(1), 2001, pp. 128-133

Abstract

Background/Aims: Interferon-based regimens (alone or with ribavairin) are standard therapies for chronic hepatitis C. The aim of this study was to compare a 24-week regimen of interferon alpha-2b + ribavirin (LFN + RIBA) to interferon alpha-2b + amantadine (IFN + AMANT) in non-responders to previous interferon monotherapy. Methods: In a multi-center, double-blind clinical trial, 118 patients (non-responders to previous interferon mono-therapy) were equally randomized into the two arms: interferon alpha-2b (3 MU thrice weekly) and ribavirin (800 mg daily) vs. interferon alpha-2b (3 MU thrice weekly) and amantadine (200 mg daily). Results: After 24 weeks of therapy, HCV RNA became undetectable in 34.8% (95% CI: 23.7-49.2) of IFN + RIBA and 19.6% (95% CI: 10.6-34.7) of IFN + AMANT (P = 0.10). This response was sustained in 3.9% (95% CI: 1.0-14.9) of IFN + RIBA and 0% of IFN + AMANT (P = 0.16). Ten patients from IFN + AMANT (17%) and 12 patients (20%) from IFN + RIBA were discontinued before completion of therapy. Of these, 7% in IPN + AMANT and 12% in IFN + RIBA were discontinued due to adverse effects. Conclusions: Re-treatment of interferon non-responders with a 24-week course of IFN + AMANT was not associated with any sustained viral eradication. Although IFN + RIBA in this group was associated with a reasonable end of treatment response, relapses were common and sustained responses were low. (C) 2001 European Association for the Study of the Liver. published by Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 06:13:42